4.3 Review

Personalized Medicine: The Road Ahead

期刊

CLINICAL BREAST CANCER
卷 11, 期 1, 页码 20-26

出版社

CIG MEDIA GROUP, LP
DOI: 10.3816/CBC.2011.n.004

关键词

Future directions; Prognostic factors

类别

向作者/读者索取更多资源

With breast cancer now being recognized as a heterogeneous disease, the concept of personalized medicine demands that the tumor of every individual be treated uniquely. This has lead to ever-expanding use of existing prognostic and predictive markers, and the search for better ones is ongoing. The classic prognostic tools such as tumor size, lymph node status, grade, hormone receptors, and HER2 status are now supplemented by gene expression based tools such as PAM50 and MammaPrint. However, the overdependence of these tools on proliferation-related genes is a significant handicap. Although pathway-based signatures hold great promise in future breast cancer prognostication, the fact that every tumor has multiple functional pathways significantly limits the utility of this approach. Developed by the integration of estrogen receptor (ER), HER2, proliferation-related, and other genes, the Oncotype DX assay has been able to provide valuable prognostic information for ER-positive tumors. Newer molecular markers based on cancer stem cells, single-nucleotide polymorphisms (SNPs), and miRNAs are becoming available, but their importance needs to be validated. It is clear that breast cancer is a multifaceted process and that none of the tools can reliably predict a binary outcome (recurrence or no recurrence). The breast cancer community is still awaiting an ideal prognostic tool that can integrate knowledge from classic variables such as tumor size and grade with new throughput technology and principles of pharmacogenomics. Such a tool will not only define prognostic subgroups but also be able to predict therapeutic efficacy and/or resistance based on molecular profiling.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis

Melinda L. Telli, Charles Chu, Sunil S. Badve, Shaveta Vinayak, Daniel P. Silver, Steven J. Isakoff, Virginia Kaklamani, William Gradishar, Vered Stearns, Roisin M. Connolly, James M. Ford, Joshua J. Gruber, Sylvia Adams, Judy Garber, Nadine Tung, Chris Neff, Ryan Bernhisel, Kirsten M. Timms, Andrea L. Richardson

CLINICAL CANCER RESEARCH (2020)

Article Oncology

Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast

Sunil S. Badve, Sanghee Cho, Yesim Gokmen-Polar, Yunxia Sui, Chrystal Chadwick, Elizabeth McDonough, Anup Sood, Marian Taylor, Maria Zavodszky, Puay Hoon Tan, Michael Gerdes, Adrian L. Harris, Fiona Ginty

Summary: Limited knowledge about DCIS cellular composition and its relationship with breast cancer events (BCE) was investigated using immunofluorescence multiplexing (MxIF). A total of 32 cellular biomarkers in FFPE DCIS tissue microarrays from 51 patients were analyzed, revealing significant correlations between ER, PR, HER2, and BCE. Clustering analysis identified 6 distinct cell groups, with clusters 2, 4 showing low BCE risk associations and cluster 6 showing increased risk. The continuous expression score (Escore) based on these clusters predicted likelihood of BCE, indicating the potential for novel biomarker analysis and prediction of BCE using this method. Further validation of Escore in a larger cohort is necessary.

BRITISH JOURNAL OF CANCER (2021)

Article Oncology

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group

Torsten O. Nielsen, Samuel C. Y. Leung, David L. Rimm, Andrew Dodson, Balazs Acs, Sunil Badve, Carsten Denkert, Matthew J. Ellis, Susan Fineberg, Margaret Flowers, Hans H. Kreipe, Anne-Vibeke Laenkholm, Hongchao Pan, Friderique M. Penault-Llorca, Mei-Yin Polley, Roberto Salgado, Ian E. Smith, Tomoharu Sugie, John M. S. Bartlett, Lisa M. McShane, Mitch Dowsett, Daniel F. Hayes

Summary: Ki67 immunohistochemistry (IHC) is commonly used in breast cancer as a proliferation marker, but its analytical validity has been questioned. The International Ki67 in Breast Cancer Working Group (IKWG) recommends careful preanalytical handling, adoption of a standardized visual scoring method, and participation in quality assurance and quality control programs. Clinical utility of Ki67 IHC in breast cancer care is currently limited to prognosis assessment in stage I or II breast cancer.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Article Oncology

Thymic Hyperplasia with Lymphoepithelial Sialadenitis (LESA)-Like Features: Strong Association with Lymphomas and Non-Myasthenic Autoimmune Diseases

Stefan Porubsky, Zoran V. Popovic, Sunil Badve, Yara Banz, Sabina Berezowska, Dietmar Borchert, Monika Brueggemann, Timo Gaiser, Thomas Graeter, Peter Hollaus, Katrin S. Huettl, Michaela Kotrova, Andreas Kreft, Christian Kugler, Fabian Lotscher, Burkhard Moller, German Ott, Gerhard Preissler, Eric Roessner, Andreas Rosenwald, Philipp Stroebel, Alexander Marx

Summary: Thymic hyperplasia with LESA-like features (LESA-like TH) is associated with lymphomas in 14% of cases and partially overlapping autoimmune diseases in 33% of cases. A hematologic and rheumatologic workup should be standard in patients diagnosed with LESA-like TH, particularly those with autoimmune diseases. Radiologists and clinicians should consider LESA-like TH as a potential differential diagnosis for mediastinal mass lesions in patients with autoimmune diseases.

CANCERS (2021)

Review Oncology

Thymic Carcinomas and Second Malignancies: A Single-Center Review

Sunil S. Badve, Rachel Dougherty, Michael Balatico, Kenneth A. Kesler, Patrick Loehrer, Yesim Gokmen-Polar

Summary: Thymic carcinoma, a rare and aggressive tumor, accounts for less than 0.01% of all tumors. The incidence of second malignancies in patients with thymic carcinomas is similar to that reported for thymomas. Abnormalities in immunological surveillance may be responsible for this high incidence of second malignancies in thymic tumors.

CANCERS (2021)

Review Oncology

Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130

Sunil S. Badve, Frederique Penault-Llorca, Jorge S. Reis-Filho, Regula Deurloo, Kalliopi P. Siziopikou, Corrado D'Arrigo, Giuseppe Viale

Summary: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer. Increased tumor-infiltrating lymphocyte counts have been found to be prognostic for survival in TNBC. Anti-PD-L1 and anti-PD-1 antibodies have been approved for the treatment of TNBC, and PD-L1 testing is becoming increasingly important in guiding treatment options.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Article Oncology

Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial

Rafael Caparica, Yaohua Ma, Claudia De Angelis, Francois Richard, Christine Desmedt, Ahmad Awada, Martine Piccart, Edith A. Perez, Alvaro Moreno-Aspitia, Sunil Badve, E. Aubrey Thompson, Evandro de Azambuja

Summary: In this post-hoc analysis of the NCCTG-N9831 trial, a high expression of the beta 2AR gene (ADRB2) was associated with longer disease-free survival and identified patients who benefited from adjuvant trastuzumab in HER2-positive breast cancer.

CLINICAL BREAST CANCER (2022)

Article Oncology

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer

Sherene Loi, Roberto Salgado, Sylvia Adams, Giancarlo Pruneri, Prudence A. Francis, Magali Lacroix-Triki, Heikki Joensuu, Maria Vittoria Dieci, Sunil Badve, Sandra Demaria, Robert Gray, Elisabetta Munzone, Damien Drubay, Jerome Lemonnier, Christos Sotiriou, Pirkko Liisa Kellokumpu-Lehtinen, Andrea Vingiani, Kathryn Gray, Fabrice Andre, Carsten Denkert, Martine Piccart, Elvire Roblin, Stefan Michiels

Summary: The importance of integrating biomarkers such as TILs into the TNM staging system for TNBC has been emphasized in the AJCC 8th Edition. Studies show that TILs can significantly influence the traditional pathological staging, suggesting that considering TILs in addition to stage can lead to better outcomes for TNBC patients.

NPJ BREAST CANCER (2022)

Article Oncology

Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

Milan Radovich, Jeffrey P. Solzak, Chao J. Wang, Bradley A. Hancock, Sunil Badve, Sandra K. Althouse, Steven M. Bray, Anna Maria V. Storniolo, Tarah J. Ballinger, Bryan P. Schneider, Kathy D. Miller

Summary: The combination of gedatolisib and cofetuzumab pelidotin, targeting both the PI3K and Wnt pathways, demonstrates promising clinical activity in metastatic TNBC. This phase I clinical trial shows that the treatment is well tolerated and has potential efficacy in inhibiting disease progression.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Is conservative management of ductal carcinoma in situ risky?

Lan Zheng, Yesim Gokmen-Polar, Sunil S. Badve

Summary: The nonsurgical management of ductal carcinoma in situ (DCIS) is controversial with limited understanding of its long-term consequences. This study aimed to assess the risk of upstaging to invasive carcinoma and ipsilateral breast cancer events in patients eligible for nonsurgical management trials. The results showed that these patients had a significantly high risk of developing ipsilateral breast events within 5 years of diagnosis, indicating the need for better selection criteria to identify patients at very low risk for the development of invasive breast cancer (IBC).

NPJ BREAST CANCER (2022)

Article Pathology

Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

Balazs Acs, Samuel C. Y. Leung, Kelley M. Kidwell, Indu Arun, Renaldas Augulis, Sunil S. Badve, Yalai Bai, Anita L. Bane, John M. S. Bartlett, Jane Bayani, Gilbert Bigras, Annika Blank, Henk Buikema, Martin C. Chang, Robin L. Dietz, Andrew Dodson, Susan Fineberg, Cornelia M. Focke, Dongxia Gao, Allen M. Gown, Carolina Gutierrez, Johan Hartman, Zuzana Kos, Anne-Vibeke Laenkholm, Arvydas Laurinavicius, Richard M. Levenson, Rustin Mahboubi-Ardakani, Mauro G. Mastropasqua, Sharon Nofech-Mozes, C. Kent Osborne, Frederique M. Penault-Llorca, Tammy Piper, Mary Anne Quintayo, Tilman T. Rau, Stefan Reinhard, Stephanie Robertson, Roberto Salgado, Tomoharu Sugie, Bert van der Vegt, Giuseppe Viale, Lila A. Zabaglo, Daniel F. Hayes, Mitch Dowsett, Torsten O. Nielsen, David L. Rimm

Summary: This study demonstrates certain comparability differences between core biopsy samples and corresponding resection specimens in Ki67 measurement, likely due to pre-analytical factors. Therefore, Ki67 immunohistochemistry should be tested on core biopsy samples as a priority to better reflect the biological status of the tumor.

MODERN PATHOLOGY (2022)

Article Oncology

Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast

Sunil S. Badve, Sanghee Cho, Xiaoyu Lu, Sha Cao, Soumya Ghose, Aye Aye Thike, Puay Hoon Tan, Idris Tolgay Ocal, Daniele Generali, Fabrizio Zanconati, Adrian L. Harris, Fiona Ginty, Yesim Gokmen-Polar

Summary: The study investigated the prognostic role of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) in multi-national cohorts from Asian and European women. It found that older women with circumferential TILs were less likely to develop second breast cancer events (BCE) at a 5-year follow-up. The spatial arrangement of TILs may serve as a better prognostic indicator in DCIS cases.

CANCERS (2022)

Editorial Material Oncology

Artificial intelligence in breast pathology - dawn of a new era

Sunil S. Badve

Summary: This article discusses the use of artificial intelligence methods for analyzing pathology slides. The authors describe a reliable second reader system that can differentiate in situ and advanced invasive carcinomas from non-neoplastic lesions of the breast.

NPJ BREAST CANCER (2023)

Article Oncology

Predicting Breast Cancer Events in Ductal Carcinoma In Situ (DCIS) Using Generative Adversarial Network Augmented Deep Learning Model

Soumya Ghose, Sanghee Cho, Fiona Ginty, Elizabeth McDonough, Cynthia Davis, Zhanpan Zhang, Jhimli Mitra, Adrian L. Harris, Aye Aye Thike, Puay Hoon Tan, Yesim Gokmen-Polar, Sunil S. Badve

Summary: The authors developed a deep learning classification network to predict breast cancer events (BCEs) in patients with ductal carcinoma in situ (DCIS), providing early and accurate predictions for personalized therapy and avoiding over-treatment of low-risk patients.

CANCERS (2023)

Article Pharmacology & Pharmacy

Targeting the Tumor-Tumor Microenvironment Crosstalk

Sunil S. S. Badve, Yesim Gokmen-Polar

Summary: Cancer development and progression is a complex process influenced by the co-evolution of cancer cells and their microenvironment. Traditional anti-cancer therapy mainly targets cancer cells, but considering the complex interactions between the tumor and its microenvironment may improve drug efficacy.

EXPERT OPINION ON THERAPEUTIC TARGETS (2023)

暂无数据